Results 81 to 90 of about 4,504 (155)

Pharmacologic and clinical evaluation of posaconazole. [PDF]

, 2016
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of
Healy, Jason R., Moore, Jason N., Kraft, Walter K.   +2 more
core   +1 more source

A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, Volume 209, Issue 3, Page 1198-1207, September 2026.
Early letermovir initiation (day 0) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) reduced early cytomegalovirus (CMV) infection and delayed first CMV DNAemia compared with later starts. Extending prophylaxis to 200 days virtually eliminated late CMV reactivation and improved 1‐year overall survival, with no grade ≥3 drug‐related
Shiyu Chen, Zhihang Su, Xiaohan Zhang, Xiaoqing Li, Xin Du   +4 more
wiley   +1 more source

Role of posaconazole in the treatment of oropharyngeal candidiasis

, 2010
Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz11Section of Infectious Diseases and Department of Medicine, 2School of Pharmacy, University of Arizona, Tucson, Arizona, USAAbstract: Posaconazole is the newest azole antifungal approved by the US ...
Voichita Ianas, Stephen A Klotz, Kathryn R Matthias   +2 more
core  

Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir

Scientific Reports
The increasing incidence and dissemination of multidrug-resistant Candida auris represents a serious global threat. The emergence of pan-resistant C. auris exhibiting resistance to all three classes of antifungals magnifies the need for novel therapeutic
Yehia Elgammal, Ehab A. Salama, Mohamed N. Seleem   +2 more
doaj   +1 more source

Real‐Life Study on Gilteritinib‐Related Infections (GilteRInf): An Italian SEIFEM Study

American Journal of Hematology, Volume 101, Issue 10, Page 2672-2676, October 2026.
Elisa Buzzatti, Irene Terrenato, Martina Tomassi, Federica Lessi, Sara Pezone, Cristina Papayannidis, Gianluca Martini, Fabio Forghieri, Luana Fianchi, Martina Quattrone, Nicola Fracchiolla, Claudio Fozza, Michela Abbenante, Anna Lina Piccioni, Davide Facchinelli, Claudia Maria Basilico, Caterina Buquicchio, Nicola Di Renzo, Monica Piedimonte, Maria Giovanna Cefalo, Daniele Armiento, Adriano Venditti, Alessandro Busca, Francesco Marchesi, Maria Ilaria Del Principe, Livio Pagano   +25 more
wiley   +1 more source

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

British Journal of Haematology, Volume 209, Issue 3, Page 1386-1390, September 2026.
In FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty‐two per cent of patients treated with intention‐to‐transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain
Wei Yee Chan, Hannah Al‐Yousuf, Ho Pui Jeff Lam, Sarah Leong, Jiexin Zheng, Richard Burt, Andrew J. Wilson, Ke Xu, Kate Stringaris, Samah Alimam, Kavita Raj, Rajeev Gupta, Panagiotis Kottaridis, Anish Tailor, Rebecca Burgoyne, Marc R. Mansour, Asim Khwaja, Rob Sellar, Elspeth M. Payne, Jenny O'Nions   +19 more
wiley   +1 more source

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis

, 2019
Pannee Leelawattanachai,1,2 Preecha Montakantikul,1 Wichit Nosoongnoen,1 Methee Chayakulkeeree31Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 2Department of Pharmacy, Faculty of ...
Chayakulkeeree M, Montakantikul P, Leelawattanachai P, Nosoongnoen W   +3 more
core  

Posaconazole-Induced Hypertension and Hypokalemia: Mechanistic Evaluation

, 2017
Background Recent studies have shown the new posaconazole delayed-release tablets have superior bioavailability compared with the liquid suspension formulation.
Ian Mchardy, George R Thompson, Diana Chang, Rebecca Wittenberg, Alison Semrad   +4 more
core   +1 more source

Posaconazole therapeutic drug monitoring in pediatrics: a single-center retrospective study

BMC Pediatrics
Background Invasive fungal infections are associated with high morbidity and mortality in immunosuppressed pediatric patients. Posaconazole is commonly used for both prophylaxis and treatment of invasive fungal infections.
Khalid W. Taher, Razan Almofada, Hala Hijazi, Aiman Y. Alwadi, Ahmed A. Albassam, Abdullah Alsultan   +5 more
doaj   +1 more source

Prediction of Tacrolimus–Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models

Pharmaceutics
Objective: Posaconazole, a second-generation triazole antifungal used for the prevention or treatment of invasive fungal infections, has been shown to markedly increase tacrolimus exposure in vivo when co-administered, potentially leading to clinically ...
Mengmeng Guan, Wanyi Zhou, Haoran Qin, Yi Xu, Di Zhao, Hui Xue, Nan Hu   +6 more
doaj   +1 more source